A Placebo‐controlled Double‐blind Study of Epalrestat (ONO‐2235) in Patients with Diabetic Neuropathy

Diabetic Medicine

Volumn 10, Issue 2 S, 1993, Pages 39S-43S

  Goto, Yoshio ^a   Hotta, Nigishi ^b   Shigeta, Yukio ^d   Sakamoto, Nobuo ^b   Kito, Shozo ^e   Matsuoka, Kenpei ^f   Takahashi, Akira ^c   Kikkawa, Ryuichi ^d   Sakuma, Akira ^g  

^a Tohoku Kouseinenkin Hospital   (Japan)

^b Third Department of Internal Medicine   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^f SAISEIKAI CENTRAL HOSPITAL   (Japan)

^g TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aldose reductase inhibitor; Clinical trials; Diabetic neuropathy; Epalrestat; Haemoglobin A1C; Nerve conduction velocity

Indexed keywords

EPALRESTAT; HEMOGLOBIN A1C;

BLISTER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ALDEHYDE REDUCTASE; COMPARATIVE STUDY; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMAN; MEDIAN NERVE; MIDDLE AGE; NEURAL CONDUCTION; PERONEAL NERVE; PLACEBOS; RHODANINE;

EID: 0027278989     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.1993.tb00197.x     Document Type: Article

References (16)

1. Hyperglycemia, polyol metabolism and complications of diabetes mellitus
2. Glucose‐induced alterations in nerve metabolism: Current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy
3. Altered myo‐inositol metabolism in diabetic nerve
4. Aldose reductase inhibitors
5. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: Relief of pain and improved somatic and autonomic nerve function
6. Aldose reductase inhibitor improves nerve conduction velocity in diabetic patients
7. Clinical study of a new aldose reductase inhibitor (ONO‐2235) on diabetic neuropathy: Clinical results with 10 institutes in Japan
8. Clinical evaluation of an aldose reductase inhibitor, ONO‐2235 on diabetic neuropathy; A double‐blind comparative study
9. Effects of a fructose‐rich diet and an aldose reductase inhibitor on the development of diabetic neuropathy in streptozotocin‐treated rats
10. Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus
11. Prevention of peripheral nerve dysfunction by aldose reductase inhibitor in streptozotocin‐diabetic rats
12. Effects of a fructose‐rich diet and the aldose reductase inhibitor, ONO‐2235, on the development of diabetic neuropathy in streptozotocin‐treated rats
13. Nerve glucose, fructose, sorbitol, myoinositol and fiber degeneration and regeneration in diabetic neuropathy
14. Regeneration and repair of myelinated fibers in sural‐nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil
15. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973